Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Med Oncol. 2012 Dec;29(5):3162-8. doi: 10.1007/s12032-012-0231-y. Epub 2012 Apr 22.
N-Myc downstream-regulated gene 2 (NDRG2) has been demonstrated to influence the metastatic potential of hepatocellular carcinoma and breast cancer cells by regulating CD24 expression. The aim of this study was to investigate the roles of NDRG2 and CD24 in the clinical pathology of lung adenocarcinoma and to explore whether the expression of these two markers can be used as independent factors for the prediction of prognosis in patients with this tumor. NDRG2 and CD24 expression in paraffin-embedded specimens gathered from 166 patients with lung adenocarcinoma was detected by immunohistochemical method. The correlation of these two proteins expression with clinicopathological parameters and prognosis was statistically analyzed. NDRG2 and CD24 proteins were highly expressed in 59/166 (35.5 %) and 110/166 (66.3 %) of lung adenocarcinoma patients, respectively. High expression of NDRG2 was frequently found in lung adenocarcinoma tissues in early pTNM stage (p = 0.01) and without pathological metastasis (p = 0.02), whereas the high expression of CD24 was significantly associated with the advanced pTNM stage (p = 0.04) and pathological metastasis (p = 0.01). Univariate analysis indicated that the patients with NDRG2 high expression correlated with favorable prognosis in patients with lung adenocarcinoma (p = 0.001), as opposed to CD24 (p = 0.001). The survival rate of the patients with NDRG2-low/CD24-high expression was the lowest (p < 0.001). Multivariate statistical analysis showed that the conjoined expressions of NDRG2-high/CD24-low and NDRG2-low/CD24-high were independent prognostic indicators of lung adenocarcinoma (p = 0.03 and p = 0.02, respectively). Our results suggest that the decreased expression of NDRG2 or the increased expression of CD24 is an important feature of lung adenocarcinoma. A combined detection of NDRG2/CD24 co-expression may benefit us in prediction of the prognosis of lung adenocarcinoma.
N- 神经嵴衍生调节因子 2（NDRG2）已被证明通过调节 CD24 的表达来影响肝癌和乳腺癌细胞的转移潜能。本研究旨在探讨 NDRG2 和 CD24 在肺腺癌临床病理学中的作用，并探讨这两种标志物的表达是否可作为预测肿瘤患者预后的独立因素。通过免疫组织化学方法检测了来自 166 例肺腺癌患者石蜡包埋标本中 NDRG2 和 CD24 的表达。对这两种蛋白表达与临床病理参数和预后的相关性进行了统计学分析。NDRG2 和 CD24 蛋白在 166 例肺腺癌患者中分别有 59/166（35.5%）和 110/166（66.3%）高表达。NDRG2 高表达常发生于早期 pTNM 期（p = 0.01）和无病理转移的肺腺癌组织（p = 0.02），而 CD24 高表达与晚期 pTNM 期（p = 0.04）和病理转移（p = 0.01）显著相关。单因素分析表明，NDRG2 高表达的患者与肺腺癌患者的预后良好相关（p = 0.001），而与 CD24 相反（p = 0.001）。NDRG2 低/CD24 高表达患者的生存率最低（p < 0.001）。多因素统计分析显示，NDRG2 高/CD24 低和 NDRG2 低/CD24 高的联合表达是肺腺癌的独立预后指标（p = 0.03 和 p = 0.02）。我们的结果表明，NDRG2 表达降低或 CD24 表达增加是肺腺癌的一个重要特征。联合检测 NDRG2/CD24 共表达可能有助于预测肺腺癌的预后。
